Literature DB >> 16985878

The role of estrogens in prostate carcinogenesis: a rationale for chemoprevention.

Maarten C Bosland.   

Abstract

Estrogens as hormonal therapy, particularly diethylstilbestrol, are effective against androgen-dependent prostate cancer, but paradoxically estrogens might also be involved in the causation of this malignancy. Therefore, antiestrogens have been suggested as both a chemopreventive and chemotherapeutic treatment, thereby inhibiting the development and progression of prostate cancer. This review addresses the role of estrogens in prostate carcinogenesis and prostate cancer progression and examines the rationale for using antiestrogenic agents in chemoprevention of prostate cancer.

Entities:  

Year:  2005        PMID: 16985878      PMCID: PMC1477605     

Source DB:  PubMed          Journal:  Rev Urol        ISSN: 1523-6161


  51 in total

1.  Mechanism of lower genotoxicity of toremifene compared with tamoxifen.

Authors:  S Shibutani; A Ravindernath; I Terashima; N Suzuki; Y R Laxmi; Y Kanno; M Suzuki; T I Apak; J J Sheng; M W Duffel
Journal:  Cancer Res       Date:  2001-05-15       Impact factor: 12.701

Review 2.  Selective estrogen receptor modulation: concept and consequences in cancer.

Authors:  V Craig Jordan
Journal:  Cancer Cell       Date:  2004-03       Impact factor: 31.743

Review 3.  Estrogens as endogenous genotoxic agents--DNA adducts and mutations.

Authors:  E Cavalieri; K Frenkel; J G Liehr; E Rogan; D Roy
Journal:  J Natl Cancer Inst Monogr       Date:  2000

4.  Gene expression profiling of testosterone and estradiol-17 beta-induced prostatic dysplasia in Noble rats and response to the antiestrogen ICI 182,780.

Authors:  Christopher J Thompson; Neville N C Tam; Jennifer M Joyce; Irwin Leav; Shuk-Mei Ho
Journal:  Endocrinology       Date:  2002-06       Impact factor: 4.736

5.  Evaluation of androgen, estrogen (ER alpha and ER beta), and progesterone receptor expression in human prostate cancer by real-time quantitative reverse transcription-polymerase chain reaction assays.

Authors:  A Latil; I Bièche; D Vidaud; R Lidereau; P Berthon; O Cussenot; M Vidaud
Journal:  Cancer Res       Date:  2001-03-01       Impact factor: 12.701

6.  5-alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males.

Authors:  R K Ross; L Bernstein; R A Lobo; H Shimizu; F Z Stanczyk; M C Pike; B E Henderson
Journal:  Lancet       Date:  1992-04-11       Impact factor: 79.321

7.  Induction of a DNA adduct detectable by 32P-postlabeling in the dorsolateral prostate of NBL/Cr rats treated with estradiol-17 beta and testosterone.

Authors:  X Han; J G Liehr; M C Bosland
Journal:  Carcinogenesis       Date:  1995-04       Impact factor: 4.944

8.  Resveratrol induces apoptosis in LNCaP cells and requires hydroxyl groups to decrease viability in LNCaP and DU 145 cells.

Authors:  Gary Z Morris; Roy L Williams; Mark S Elliott; Stephen J Beebe
Journal:  Prostate       Date:  2002-09-01       Impact factor: 4.104

9.  Induction at high incidence of ductal prostate adenocarcinomas in NBL/Cr and Sprague-Dawley Hsd:SD rats treated with a combination of testosterone and estradiol-17 beta or diethylstilbestrol.

Authors:  M C Bosland; H Ford; L Horton
Journal:  Carcinogenesis       Date:  1995-06       Impact factor: 4.944

10.  Endogenous sex hormones and prostate cancer: a quantitative review of prospective studies.

Authors:  N E Eaton; G K Reeves; P N Appleby; T J Key
Journal:  Br J Cancer       Date:  1999-06       Impact factor: 7.640

View more
  19 in total

1.  Estrogen Exhibits a Biphasic Effect on Prostate Tumor Growth through the Estrogen Receptor β-KLF5 Pathway.

Authors:  Yuka Nakajima; Asami Osakabe; Tsuyoshi Waku; Takashi Suzuki; Kensuke Akaogi; Tetsuya Fujimura; Yukio Homma; Satoshi Inoue; Junn Yanagisawa
Journal:  Mol Cell Biol       Date:  2015-10-19       Impact factor: 4.272

Review 2.  Estrogens in Male Physiology.

Authors:  Paul S Cooke; Manjunatha K Nanjappa; CheMyong Ko; Gail S Prins; Rex A Hess
Journal:  Physiol Rev       Date:  2017-07-01       Impact factor: 37.312

3.  Estrogen action and prostate cancer.

Authors:  Jason L Nelles; Wen-Yang Hu; Gail S Prins
Journal:  Expert Rev Endocrinol Metab       Date:  2011-05

4.  DNA methylation in promoter region as biomarkers in prostate cancer.

Authors:  Mihi Yang; Jong Y Park
Journal:  Methods Mol Biol       Date:  2012

Review 5.  Modifiable risk factors for prostate cancer in low- and lower-middle-income countries: a systematic review and meta-analysis.

Authors:  Filipe Cirne; Coralea Kappel; Shijie Zhou; Som D Mukherjee; Mahshid Dehghan; Jo-Anne Petropoulos; Darryl P Leong
Journal:  Prostate Cancer Prostatic Dis       Date:  2022-07-05       Impact factor: 5.455

Review 6.  EDC-2: The Endocrine Society's Second Scientific Statement on Endocrine-Disrupting Chemicals.

Authors:  A C Gore; V A Chappell; S E Fenton; J A Flaws; A Nadal; G S Prins; J Toppari; R T Zoeller
Journal:  Endocr Rev       Date:  2015-11-06       Impact factor: 19.871

Review 7.  Male reprotoxicity and endocrine disruption.

Authors:  Sarah Campion; Natasha Catlin; Nicholas Heger; Elizabeth V McDonnell; Sara E Pacheco; Camelia Saffarini; Moses A Sandrof; Kim Boekelheide
Journal:  Exp Suppl       Date:  2012

8.  Dimethandrolone (7alpha,11beta-dimethyl-19-nortestosterone) and 11beta-methyl-19-nortestosterone are not converted to aromatic A-ring products in the presence of recombinant human aromatase.

Authors:  Barbara J Attardi; Trung C Pham; Lisa C Radler; Janet Burgenson; Sheri A Hild; Jerry R Reel
Journal:  J Steroid Biochem Mol Biol       Date:  2008-06       Impact factor: 4.292

Review 9.  Soy isoflavones and prostate cancer: a review of molecular mechanisms.

Authors:  Abeer M Mahmoud; Wancai Yang; Maarten C Bosland
Journal:  J Steroid Biochem Mol Biol       Date:  2013-12-25       Impact factor: 4.292

Review 10.  Racial disparities in prostate cancer: a molecular perspective.

Authors:  Arun Bhardwaj; Sanjeev K Srivastava; Mohammad Aslam Khan; Vijay K Prajapati; Seema Singh; James E Carter; Ajay P Singh
Journal:  Front Biosci (Landmark Ed)       Date:  2017-01-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.